Core Viewpoint - The overall trend of acute respiratory infectious diseases in China is currently declining, as reported by the Chinese Center for Disease Control and Prevention (CDC) [1]. Group 1: Current Situation of Respiratory Diseases - The CDC is continuously monitoring flu-like cases and severe acute respiratory infection cases in hospitals across the country [1]. - The positive detection rates for respiratory samples in sentinel hospitals show that the top three pathogens are influenza virus, respiratory syncytial virus, and rhinovirus, all of which are known common pathogens [1]. - There have been no discoveries of unknown pathogens or new infectious diseases related to these respiratory infections [1]. Group 2: Flu Trends and Statistics - The current flu epidemic in China is at a low level, with a continuous decline over the past two months [1]. - The positive detection rate of influenza virus, the number of reported cases, and the number of reported outbreaks are all on a downward trend [1]. - The predominant circulating strain is the H3N2 subtype of influenza A, while the proportion of the Victoria lineage of influenza B has shown a slight increase [1]. Group 3: Other Respiratory Pathogens - The positive detection rate for respiratory syncytial virus is also declining, with higher rates observed in northern provinces compared to southern provinces [1]. - The positive detection rate for rhinovirus is fluctuating at a certain level [1]. - The detection rates for other monitored respiratory pathogens, including the novel coronavirus, remain low overall [1].

Core Insights - Respiratory syncytial virus (RSV) is a common respiratory pathogen in China, with seasonal outbreaks primarily occurring in autumn and winter, while some southern provinces may experience year-round circulation [1][2] - The general population is susceptible to RSV, but infants, the elderly, and individuals with chronic underlying conditions face a higher disease burden [1][2] Group 1: Infection Characteristics - RSV is the leading cause of acute respiratory infections in children, especially infants, with early symptoms resembling those of a common cold, including cough, sore throat, runny nose, and fever [2] - Severe clinical symptoms can develop, such as bronchitis and pneumonia, with rare cases leading to RSV-related encephalopathy [2] Group 2: Vulnerable Populations - Healthy adults typically exhibit mild upper respiratory symptoms upon RSV infection, but they should maintain respiratory and hand hygiene to prevent transmission [2] - Elderly individuals and those with chronic lung disease, cardiovascular disease, or immune deficiencies are at risk for severe lower respiratory infections, which may worsen heart and lung function [2]

Core Viewpoint - The company Innotech has introduced new products that cater to both B2B and B2C markets, providing testing solutions for professional medical personnel and consumers alike [1] Product Offerings - The new product line includes a respiratory series that features combined antigen test kits for respiratory syncytial virus, adenovirus, parainfluenza virus, and others using latex chromatography [1] - Additionally, the product range includes antigen test kits for influenza A and B viruses, as well as the novel coronavirus (2019-nCoV), also utilizing latex methods [1] - Other offerings consist of fecal occult blood (FOB) test kits using colloidal gold immunochromatography and Helicobacter pylori antigen test kits employing latex methods [1]

Core Viewpoint - Innotech is actively developing home testing business to meet the emerging market demand for respiratory and digestive applications, enhancing its online marketing efforts through official flagship stores and other platforms [2] Group 1: Company Overview - Innotech received an institutional research visit from Tianhong Fund on December 9, 2025, with the meeting conducted online [1] - The company’s board secretary, Chen Fukan, represented Innotech during the research meeting [2] Group 2: Product Development - Innotech's new products cater to both B-end and C-end markets, suitable for professional medical personnel and consumer self-testing [2][5] - The product lineup includes respiratory series products (e.g., combined antigen test kits for respiratory syncytial virus, adenovirus, etc.) and digestive-related products (e.g., fecal occult blood test kits, Helicobacter pylori antigen test kits) [2][6] Group 3: Sales Channels and Competitive Advantage - The C-end sales channels are primarily online, including authorized stores and self-operated flagship stores on platforms like JD.com, Taobao, and Meituan [4] - The company has established a certain level of brand recognition in the domestic respiratory pathogen detection field due to years of technical accumulation and market expansion [4] Group 4: Investment Strategy - Innotech focuses its external investments on areas that are highly synergistic with its main business, including new products, new technology platforms, and new testing fields [7] - The company conducts careful assessments and decision-making regarding related projects, with progress updates to be disclosed in accordance with regulatory requirements [7]

Core Viewpoint - The company Innotech has identified a range of home testing products that align well with current market demands, particularly in the context of respiratory and gastrointestinal infections, and is actively collaborating with major e-commerce platforms to enhance market presence [2]. Product Offerings - Innotech's product lineup includes: - Influenza A and B virus antigen test kits (colloidal gold method) - New coronavirus (2019-nCoV) antigen test kits (latex method) - Respiratory syncytial virus, adenovirus, parainfluenza virus antigen combination test kits (latex chromatography method) - Group A rotavirus, adenovirus, norovirus antigen test kits (latex chromatography method) - Fecal occult blood (FOB) test kits (colloidal gold immunochromatography method) - Helicobacter pylori antigen test kits (latex method) [2]. Market Development - The home testing market is experiencing rapid growth, driven by improvements in regulatory frameworks and clinical guidelines, indicating a promising application market for home testing products [2]. E-commerce Collaboration - The company has established partnerships with major e-commerce platforms such as JD.com, Tmall, and Meituan by setting up official flagship stores to enhance product accessibility [2].